Related Experiment Video
Updated: May 6, 2026

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
Published on: April 30, 2020
Avatrombopag in adults with immune thrombocytopenia: A multicentre real-life observational study in Madrid, Spain
Cristina Pascual-Izquierdo1, Mª Jose Llacer-Ferrandis1, Almudena de-la-Iglesia2
1Hematología, Hospital General Universitario Gregorio Marañon, Instituto de Investigación Gregorio Marañon, Madrid, Spain.
Abstract:
Immune thrombocytopenia (ITP) is a rare acquired disorder where thrombopoietin-receptor agonists have become mainstays of ITP treatment. With the recent approval of avatrombopag (AVA), real-world studies are essential to evaluate its efficacy and safety. Our study of 66 adult ITP patients treated with AVA showed a high response rate. After starting AVA, 74.2% did not require rescue medications, with minimal adverse effects. Additionally, 56.0% of patients reduced other ITP medications, and all patients aged ≥65 years responded to AVA. Results should be confirmed in larger studies, but AVA appears to be an effective and safe treatment for ITP patients.
Related Concept Videos
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Bioavailability Study Design: Healthy Subjects Versus Patients

